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Abstract
Background:  The  purpose  of  the  diagnostic  evaluation  of  adnexal  tumours  is  to  exclude  the
possibility  of  malignancy.  The  malignancy  risk  index  II  identiﬁes  patients  at  high  risk  for  ovarian
cancer. The  cut-off  value  is  greater  than  200.
Objective:  To  evaluate  the  diagnostic  accuracy  of  malignancy  risk  index  II  in  post-menopausal
women with  adnexal  tumours  in  relation  to  the  histopathological  results.
Materials  and  methods:  A  total  of  138  women  with  an  adnexal  mass  were  studied.  The  malig-
nancy risk  index  II  was  determined  in  all  of  them.  They  were  divided  into  two  groups  according
to the  histopathology  results;  69  patients  with  benign  tumours  and  69  patients  with  malignant
tumours.  A  diagnostic  test  type  analysis  was  performed  with  respect  to  the  results  of  malignancy
risk index  II  ≤  200  or  greater  than  this.
Results:  The  percentages  and  95%  conﬁdence  intervals  were  calculated.  The  accuracy  was  81.8%
(75.5--88.3),  sensitivity  76.8%  (66.9--86.7),  speciﬁcity  87%  (79.1--94.9),  with  a  positive  predic-
tive value  of  85.5%  (76.7--94.3),  and  a  negative  predictive  value  of  78.9%  (69.7--88.1).  The
positive likelihood  ratio  was  590,  and  the  negative  likelihood  ratio  was  0.266.
 Please cite this article as: Trevin˜o-Báez JD, Cantú-Cruz JA, Medina-Mercado J, Abundis A. Exactitud diagnóstica del índice de riesgo de
malignidad II en mujeres posmenopáusicas con tumor anexial. Cir Cir. 2016;84:107--112.
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Tel.: +52 (481) 381 0944.
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Conclusions:  The  malignancy  risk  index  II  has  good  performance  in  the  proper  classiﬁcation  of
post-menopausal  women  with  adnexal  masses,  both  benign  and  malignant,  with  an  accuracy  of
81.8%.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This  is
an open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Exactitud  diagnóstica  del  índice  de  riesgo  de  malignidad  II  en  mujeres
posmenopáusicas  con  tumor  anexial
Resumen
Antecedentes:  La  ﬁnalidad  en  la  evaluación  diagnóstica  de  los  tumores  anexiales  es  excluir  la
posibilidad  de  que  se  trate  de  un  proceso  maligno.  El  índice  de  riesgo  de  malignidad  II,  identiﬁca
a pacientes  con  alto  riesgo  de  presentar  cáncer  de  ovario.  Su  valor  de  corte  es  mayor  de  200.
Objetivo: Evaluar  la  exactitud  diagnóstica  del  índice  de  riesgo  de  malignidad  II  en  mujeres
posmenopáusicas  con  tumor  anexial.
Material  y  métodos: Se  estudiaron  138  mujeres  con  diagnóstico  de  masa  anexial.  A  cada  una  de
ellas se  le  determinó  el  índice  de  riesgo  de  malignidad.  Se  dividieron  en  dos  grupos  de  acuerdo  a
los resultados  de  histopatología;  69  pacientes  con  tumores  benignos  y  69  pacientes  con  tumores
malignos. Se  realizó  un  análisis  tipo  prueba  diagnóstica  con  respecto  a  los  resultados  del  índice
de riesgo  de  malignidad  II,  en  ≤  200  o  mayor  a  este.
Resultados:  Los  siguientes  porcentajes  e  intervalos  de  conﬁanza  del  95%  fueron  calculados,
exactitud  81.8%  (75.5--88.3),  sensibilidad  76.6%  (66.9--86.7),  especiﬁcidad  87%  (79.1--94.9),
valor predictivo  positivo  85.5%  (76.7--94.3),  valor  predictivo  negativo  78.9%  (69.7--88.1).  Se
obtuvo una  razón  de  verosimilitud  positiva  de  590  y  razón  de  verosimilitud  negativa  de  0.266.
Conclusiones:  El  índice  de  riesgo  de  malignidad  II  tiene  una  adecuada  eﬁciencia  en  la  clasiﬁ-
cación de  mujeres  posmenopáusicas  con  tumor  anexial,  tanto  benigno  como  maligno,  con  una
exactitud  de  la  prueba  del  81.8%.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este  es
un artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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Eackground
round  10%  of  women  at  some  point  in  their  lives  will
ndergo  a  surgical  assessment  of  an  adnexal  mass  or  for
uspected  ovarian  cancer.1
Although  the  majority  of  adnexal  tumours  are  benign,
he  principal  objective  of  diagnostic  evaluation  is  to  exclude
he  possibility  of  a  malignant  process.  The  probability  of
nding  malignancy  in  an  adnexal  tumour  which  does  not  look
alignant  is  estimated  at  4--6%.2,3
The  risk  of  malignancy  index  was  described  by  Jacobs
t  al.  in  1990,4 and  identiﬁes  patients  at  high  risk  of  ovarian
ancer.5 The  risk  of  malignancy  index  II  gives  a  rate  based
n:  ultrasound  features,  menopausal  status  and  preopera-
ive  Ca  125  levels,  and  uses  up  to  35  U/ml  as  a  normal  value
ccording  to  the  equation  below:
RM  II  =  U  ×  M  ×  Ca  125n  which  the  ultrasound  values  (U),  menopausal  status  (M)
nd  the  tumour  marker  (Ca  125)  are  multiplied;  allocating  a
core  to  each.6--8
S
b
s
cA  risk  of  malignancy  index  II  value  >  200  indicates  a  high
isk  of  malignancy.  The  risk  of  malignancy  index  II  was  more
ensitive  than  the  risk  of  malignancy  index  I  with  78%  sensi-
ivity,  89--92%  speciﬁcity.9
The  objective  of  the  study  was  to  evaluate  the  diagnostic
ccuracy  of  the  risk  of  malignancy  index  II  in  postmenopausal
omen  with  adnexal  tumours  in  relation  to  histopathological
esults.
aterial and methods
he  design  of  this  study  was  observational,  transversal,  and
nalytical  of  the  type  of  diagnostic  test.
One  hundred  and  thirty-eight  postmenopausal  women
ere  included  diagnosed  with  adnexal  tumours  by  ultra-
onography,  and  who  had  been  operated  either  by
aparoscopy  or  laparotomy  in  the  Unidad  Médica  de  Alta
specialidad  No.  23  of  the  Instituto  Mexicano  del  Seguro
ocial  in  the  city  of  Monterrey,  Nuevo  Leon;  in  the  period
etween  14  June  2011  and  17  May  2013.  A data  collection
heet  was  used  for  all  patients  to  record  their  gynaecologi-
al  variables  (menarche,  parity,  years  of  menopause,  reason
111
Table  1  Analysis  of  the  diagnostic  test.
Variable  Malignant  (n  =  69)  Benign  (n  =  69)
High  risk  53  9
Low risk 16  60
Speciﬁcity: 87% (79.1--94.9); accuracy: 81.8% (75.5--88.3); posi-
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toms  which  marked  a  statistically  signiﬁcant  difference
between  the  groups  were  increased  abdominal  volume
(p  =  0.016),  with  19  cases  in  the  malignant  tumour  group  and
Table  2  Comparison  of  demographic  characteristics
between  the  groups.
Variable  Malignant
(n  =  69)
Benign
(n  =  69)
p
Age  60  (47--86)  51.5  (44--77)  0.000*
Menarche  12  (10--16)  13  (8--17)  0.537*
OSA  20  (14--69)  20  (14--61)  0.503*
DLP  49  (35--56)  45  (40--61)  0.002*
Pregnancy  3  (0--15)  3  (0--16)  0.433*
Parity  2  (0--12)  2  (0--13)  0.314*
Caesareans  0  (0--4)  0  (0--3)  0.415*
Abortions  0  (0--5)  0  (0--4)  0.533*
Nutritional  status
Appropriate  weight  24a 10a
Overweight  24  27
Obesity  1  15  20
Obesity  2  3  12
Morbid  obesity  3  0  0.005**
OSA: onset of sexual activity; DLP: date of last menstruation; p:Malignancy  risk  index  II  in  post-menopausal  
for  consultation,  etc.),  ultrasonographic  variables,  details  of
the  surgical  procedure,  and  results  of  histopathology.
The  calculation  of  the  risk  of  malignancy  index  II  for
each  patient  was  made  using  the  formula:  IRM  II  =  U  ×  M  ×
Ca  125.  In  this  formula  U  represents  the  ultrasonographic
index,  where  multilocular  adnexal  tumours,  with  the  pres-
ence  of  solid  areas,  bilateral  lesions,  and  the  presence  of
ascitis  or  intraabdominal  metastases  are  categorised  with
a  score  each,  if  they  present  such  characteristics.  Two  or
more  characteristics  will  have  a  value  of  4  and  the  absence
of  all  ﬁndings  suggestive  of  malignancy  will  be  taken  as  1.  M
represents  menopausal  status,  one  point  for  premenopausal
women,  and  4  for  postmenopausal  women.  As  the  study  pop-
ulation  only  included  postmenopausal  women,  the  standard
value  was  4  and  the  Ca  125  level  was  applied  directly  to  the
equation.
The  patients  were  divided  into  two  groups  according  to
the  histopathology  results,  69  patients  with  benign  tumours
and  69  with  malignant  tumours.  An  association  was  made
with  contingency  tables,  taking  into  account  the  results  of
the  risk  of  malignancy  index  II  at  ≤  200  (low  risk)  or  >  200
(high  risk).
An  analysis  was  made  of  the  type  of  diagnostic  test
and  the  following  obtained:  sensitivity,  speciﬁcity,  posi-
tive  predictive  value,  positive  likelihood  ratio  and  negative
likelihood  ratio.  Descriptive  statistics  of  the  groups  were
determined;  for  the  categorical  variables  with  measures  of
frequency,  such  as:  mean  or  median  and,  dispersion  meas-
ures  such  as:  standard  deviation  and  interquartile  range.
In  the  comparative  analysis  of  the  characteristics  of  the
groups,  for  categorical  variables  Pearson’s  2 test  was  used
for  frequencies  or  where  appropriate  Fisher’s  exact  test.
The  Student’s  t-test  was  used  for  the  quantitative  variables
according  to  models  of  data  distribution  and  equality  of  vari-
ances.  The  patients  who  did  not  meet  the  requirements  were
analysed  with  the  non-parametric  Mann--Whitney  U  test.  The
statistically  signiﬁcant  value  (alpha)  was  0.05.
The  information  was  collected  on  a  database  in  Excel
2007  (Microsoft  Ofﬁce)  and  analysed  using  SPSS  software  for
Mac  version  20.
This  study  was  authorised  by  Local  Health  Research  and
Ethics  Committee  No.  1905.
Results
During  a  2  year  period  of  research  in  the  Gynaecology  --
Oncology  department  of  Unidad  Médica  de  Alta  Especiali-
dad  No.  23,  138  postmenopausal  patients  with  a  diagnosis
of  adnexal  tumour  were  studied.
With  respect  to  the  analysis  of  the  diagnostic  test  of  risk
of  malignancy  index  II  percentages  and  95%  conﬁdence  inter-
vals  (95%  CI)  were  found  for  81.8%  accuracy  (75.5--88.3),
76.8%  sensitivity  (66.9--86.7),  87%  speciﬁcity  (79.1--94.9),
positive  predictive  value  of  85.5%  (76.7--94.3)  and,  negative
predictive  value  of  78.9%  (69.7--88.1).  The  positive  likeli-
hood  ratio  was  590  and  the  negative  likelihood  ratio  was
0.266  (Table  1).With  regard  to  the  demographic  characteristics  between
groups,  it  was  found  that  the  median  age  of  the  patients  with
benign  adnexal  tumours  was  51.5,  and  the  median  age  of
the  patients  with  malignant  adnexal  tumours  was  60,  thus  ative likelihood ratio (PLR): 590; negative likelihood ratio (NLR):
0.266; sensitivity: 76.8% (66.9--86.7).
tatistically  signiﬁcant  difference  was  established  between
he  two  groups.  No  statistically  signiﬁcant  differences  were
ound  between  the  medians  of  both  groups  with  regard  to:
enarche,  onset  of  sexual  activity  or  parity.  The  median  age
t  the  date  of  last  menstruation  in  the  patients  with  benign
dnexal  tumours  was  45  and  for  the  patients  with  malignant
dnexal  tumours  it  was  49;  a  statistically  signiﬁcant  differ-
nce  was  found  (p  =  0.002).  With  regard  to  nutritional  status
he  2 test  identiﬁed  a  statistically  signiﬁcant  difference
etween  the  groups  (p  =  0.005),  an  appropriate  weight  had
 greater  typiﬁed  residue  (−1.7)  in  the  subanalysis  (Table  2).
With  respect  to  tumour  size,  in  the  category  of  tumours
rom  5  cm  to  less  than  10  cm,  a  greater  frequency  was  found
n  both  the  malignant  and  the  benign  tumour  group,  with
0  and  36  cases  respectively.  However,  in  the  category  of
umours  of  less  than  5  cm,  two  were  found  in  the  malignant
roup  and  12  in  the  benign  tumour  group,  the  2 test  showed
 statistically  signiﬁcant  difference  (p  =  0.015)  (Table  3).
The  most  frequent  clinical  signs  and  symptoms  prom-
ting  patients  to  seek  consultation  were  abdominal  pain,
ncreased  abdominal  volume,  an  incidental  ﬁnding,  and
bnormal  uterine  bleeding.  However,  the  signs  and  symp-level of statistical signiﬁcance.
a Greater typiﬁed residue in 2 test.
* Mann--Whitney U test.
** 2 test.
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Table  3  Analysis  of  the  tumour  size  between  groups.
Variable  Malignant
(n  =  69)
Benign
(n  =  69)
p
Tumour  size
<  5  cma 2  12
5--< 10  cm  30  36
10--< 15  cm  15  10
15--< 20  cm  11  6
≥ 20  cm  11  5  0.015**
p: level of statistical signiﬁcance.
a Greater typiﬁed residue in 2 test.
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Table  5  Analysis  with  2 of  surgical  background  and
complications  between  groups.
Variable  Malignant
(n  =  69)
Benign
(n  =  69)
p
Cystectomy  1  8
Unilateral
salpingo
oopherec-
tomy
5  38
Bilateral
salpingo
oopherec-
tomy
21  7
Incisional
biopsy
4  0
Ovarian
protocol1
52  2
Trans-surgical  complications
None  65  67
Haemorrhage  2  1
Intestinal
lesion
1  0
Inadvertant
puncture
0  1
Retroperi-
toneal
haematoma
1  0  0.499
Post-surgical  complications
None  64  63
Wound
infection
Surgical
3  2
PTE  0  1
Fever  1  2
Enterovesical
ﬁstula
1  0
UTI  0  1  0.617 test.
 in  the  benign  tumour  groups;  as  well  as,  being  an  inciden-
al  ﬁnding  (p  =  0.012),  with  17  cases  in  the  malignant  tumour
roup  and  31  in  the  benign  tumour  group.  The  most  frequent
ltrasound  features  of  the  adnexal  tumours  in  both  groups
ere  multilocular  cyst  with  41  cases  in  the  malignant  group
nd  25  in  the  benign  (p  =  0.006),  the  presence  of  solid  areas
ith  54  cases  in  the  malignant  tumours  and  20  in  the  benign
p  < 0.05).  The  presence  of  ascitis  was  more  frequent  in  the
alignant  tumour  group,  with  20  cases  and  only  1  in  the
enign  tumour  group;  there  was  a  statistically  signiﬁcant
ifference  (p  <  0.05)  (Table  4).
With  regard  to  the  type  of  resection  it  was  found  in  the
roup  of  benign  tumours  that  a  unilateral  salpingo  oophorec-
omy  was  the  most  frequent  procedure  (38  cases)  and  in
he  malignant  tumour  group  the  ovarian  protocol  was  used
52  cases).  The  surgical  approach  used  in  both  groups  was
n  exploratory  laparotomy.  In  general  there  were  few  trans
r  post  surgical  complications,  haemorrhage  being  the  most
requent  (>  1000  cm3)  with  3  cases  and  surgical  wound  infec-
ion  with  5  cases,  respectively;  no  statistically  signiﬁcant
alue  was  found  between  the  groups  (Table  5).
In  the  benign  tumour  group,  the  most  frequent  diagnosis
as  serous  cystadenoma  with  23  cases  and  in  the  malignant
umour  group  it  was  papillary  serous  cystadenoma  with  26
ases.
Table  4  Analysis  of  the  reasons  for  consultation  and  ultra-
sound features  between  the  groups.
Variable  Malignant
(n  =  69)
Benign
(n  =  69)
p
Urinary  symptoms  1  0  0.316**
Pain  21  21  1**
Abdominal  volume  19  8  0.016**
Digestive  symptoms 1  0  0.319**
Uterine  bleeding  9  9  1**
Incidental  ﬁnding 17  31  0.012**
Multilocular  41  25  0.006**
Bilaterality  11  6  0.195**
Solidity  54  20  0.000**
Ascitis  20  1  0.000**
p: level of statistical signiﬁcance.
** 2 test.
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pUTI: urinary tract infection; PTE: pulmonary thromboembolism.
p: level of the statistically signiﬁcant value.
iscussion
he  risk  of  malignancy  index  II  is  a  simple  algorithm  to  apply
n  clinical  practice  and  uses  laboratory  and  surgery  tests
hich  are  affordable  and  easily  reproducible.  The  risk  of
alignancy  index  was  originally  developed  by  Jacobs  et  al.4
n  1990.  Subsequently,  Tingulstad  et  al.6 developed  the  risk
f  malignancy  index  II  in  1996.  All  the  indexes  presented  a
igniﬁcantly  better  yield  in  detecting  ovarian  cancers  with
he  use  of  a  single  parameter.9
It  was  demonstrated  that  using  a  cut-off  point  of  200
irrespective  of  the  score  system)  to  evaluate  a  risk  of
alignancy  index  achieved  a sensitivity  of  between  70%
nd  87%,  and  speciﬁcity  of  89%  and  97%.  However,  the  risk
f  malignancy  index  uses  ultrasound,  which  is  operator-
ependent,  and  this  is  subject  to  the  equipment’s  image
esolution  capacity  and  possible  variation  between  patient
opulations.10,11
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Jacobs  et  al.4 reported  sensitivity  and  speciﬁcity  of  85.4%
of  96.9%,  respectively  using  the  risk  of  malignancy  index
with  a  cut-off  value  of  200.  Manjunath  et  al.12 found  73%
sensitivity  and  91%  speciﬁcity,  and  attributed  the  low  sensi-
tivity  to  the  high  percentage  of  premenopausal  women  with
ovarian  cancer,  compared  with  the  initial  studies  of  Jacobs
et  al.4,9,10
Several  studies  have  demonstrated  that  the  risk  of  malig-
nancy  index  provides  high  levels  of  sensitivity,  speciﬁcity
and  predictive  values  for  evaluating  adnexal  tumours.  How-
ever,  a  limitation  with  any  study  of  a  diagnostic  test  is
that  unlike  sensitivity  and  speciﬁcity,  the  predictive  values
change  according  to  the  prevalence  of  the  disease  in  a  pop-
ulation.  In  our  study  the  predictive  values  are  subject  to
a  50%  prevalence  because  of  the  way  the  sample  was  col-
lected  with  two  groups  of  an  equal  number  of  participants
in  relation  to  the  diagnosis  of  adnexal  tumour.  However,  the
likelihood  ratios  which  reﬂect  the  predictive  yield  of  a  test
regardless  of  the  prevalence  were  obtained  and  in  the  case
of  our  study  they  showed  an  excellent  positive  likelihood
ratio  and  a  moderate  negative  likelihood  ratio.  The  calcu-
lation  of  the  risk  of  malignancy  index  was  considered  the
method  of  choice  as  preoperative  screening  in  patients  with
an  adnexal  tumour.10,13
In  our  study  no  relationship  was  observed  between  obe-
sity  and  greater  frequency  of  malignancy  in  contrast  to  other
studies  such  as  that  of  Dótlic  et  al.13 where  they  mention  the
correlation  between  the  high  values  of  the  body  mass  index
and  the  malignant  histopathological  results.
A  variety  of  methods  for  the  early  detection  of  ovar-
ian  cancer  have  been  investigated,  an  example  is  human
epididymis  protein  4,  which  is  over-expressed  in  ovarian  can-
cer,  especially  in  serous  epithelial  tumours.  This  new  marker
has  shown  a  similar  sensitivity  to  Ca-125,  but  greater  speci-
ﬁcity  to  distinguish  between  patients  with  ovarian  cancer
and  those  with  benign  gynaecological  disorders.8,14,15
It  is  recommended  that  this  study  should  be  extended
to  premenopausal  women  because  up  to  10%  of  adnexal
tumours  are  malignant  in  this  population.  The  results  of  the
risk  of  malignancy  index  II  can  help  to  distinguish  benign
neoplasms  which  can  be  resected  by  the  gynaecologist  or
otherwise  detect  malign  neoplasms  with  a  view  to  referring
these  patients  to  the  oncological  gynaecologist  to  be  appro-
priately  staged  and  to  beneﬁt  from  optimal  cytoreduction  in
the  event  that  they  present  disease  evaluated  according  to
metastatic  stage. 8,16,17
It  is  important  to  mention  that,  although  not  part  of
the  study  objectives,  all  the  surgical  approaches  were  via
laparotomy,  which  might  imply  a  difference  with  the  laparo-
scopic  route  in  the  analysis.
Conclusions
The  risk  of  malignancy  index  II  performs  well  in  the  appro-
priate  classiﬁcation  of  postmenopausal  women  with  adnexal
tumours,  both  benign  and  malignant;  the  test  has  81.8%
accuracy  and  95%  CI  of  75.5--88.3%.The  risk  of  malignancy  index  II  is  a  reliable  test  for  pre-
operative  screening  of  postmenopausal  women  with  adnexal
tumours,  with  adequate  values  of  positive  likelihood  ratio,
negative  likelihood  ratio,  sensitivity  and  speciﬁcity,  and113
herefore  it  is  recommended  that  it  should  always  be  cal-
ulated.
It  is  recommended  that  menopausal  patients,  especially
lderly  patients,  with  a  risk  of  malignancy  index  II  greater
han  200  should  be  referred  to  a  third  level  healthcare  cen-
re  where  staging  surgery  for  the  risk  of  ovarian  cancer  can
e  performed  if  necessary.
It is  considered  appropriate  that  there  should  be  a  for-
at  for  calculating  the  risk  of  malignancy  index  II  and  apply
t  systematically  to  every  woman  with  an  adnexal  tumour,
egardless  of  her  age  or  menopausal  status  in  order  to  screen
or  ovarian  cancer.
It  is  advisable  that  this  study  should  be  extended  to  pre-
enopausal  women  in  order  to  detect  adnexal  disease  early,
nd  to  make  comparisons  between  the  sensitivity  and  speci-
city  values  of  the  risk  of  malignancy  index  II  in  pre  and
ost-menopausal  women.
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